CXCL13 and brain disorder: ICV administration of anti-CXCL13, which restricted the treatment to the CNS, allowed us to uniquely determine that the observed attenuation of the behavioral manifestations was due to changes in the brain disease progression and not simply secondary to any undetected changes in systemic disease.